论文部分内容阅读
目的观察阿托伐他汀联合曲美他嗪治疗老年冠心病左心功能不全的治疗效果,并评价其安全性。方法将90例老年冠心病左心功能不全患者并随机分为试验组和对照组各45例。对照组患者给予常规治疗,试验组在常规治疗的基础上给予阿托伐他汀与曲美他嗪进行治疗。比较2组患者服药2年后的治疗效果;同时检查患者在治疗前后左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)以及左心室收缩末期内径(LVESD)变化情况,并评估患者NYHA心功能分级;另外密切关注患者在治疗期间出现的不良反应。结果试验组总有效率为93.3%高于对照组的75.6%,差异有统计学意义(P<0.05)。与治疗前比较,治疗后2组患者LVEF均升高,LVEDD、LVESD均降低,且试验组变化幅度大于对照组,差异均有统计学意义(P<0.05)。试验组Ⅰ、Ⅱ级患者的所占比例明显高于对照组,差异有统计学意义(P<0.05)。2组患者不良反应发生率比较差异无统计学意义(P>0.05)。结论阿托伐他汀联合曲美他嗪治疗老年冠心病左心功能不全的治疗效果较好,且安全性较高,值得推广。
Objective To observe the therapeutic effect of atorvastatin combined with trimetazidine in the treatment of left ventricular dysfunction in elderly patients with coronary heart disease and to evaluate its safety. Methods 90 cases of elderly patients with left ventricular dysfunction and coronary heart disease were randomly divided into experimental group and control group of 45 cases. Patients in the control group were given conventional treatment. The experimental group was given atorvastatin and trimetazidine for treatment based on the conventional treatment. The therapeutic effect was compared between the two groups after 2 years of treatment. The changes of left ventricular ejection fraction (LVEF), left ventricular end-diastolic dimension (LVEDD) and left ventricular end-systolic diameter (LVESD) before and after treatment were also evaluated. NYHA class of cardiac function; In addition, pay close attention to patients during the treatment of adverse reactions. Results The total effective rate of the experimental group was 93.3% higher than that of the control group (75.6%), the difference was statistically significant (P <0.05). Compared with those before treatment, LVEF, LVEDD and LVESD in both groups were decreased after treatment, and the changes in the experimental group were greater than those in the control group (P <0.05). The proportion of patients in test group Ⅰ and Ⅱ was significantly higher than that in control group (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion Atorvastatin combined with trimetazidine treatment of elderly patients with left heart failure of coronary heart disease is better, more safe and worthy of promotion.